Literature DB >> 24891322

Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.

Ganesan Keerthivasan1, Yang Mei1, Baobing Zhao1, Ling Zhang2, Chad E Harris3, Juehua Gao1, Ashley A Basiorka2, Matthew J Schipma4, James McElherne1, Jing Yang1, Amit K Verma5, Andrea Pellagatti6, Jacqueline Boultwood6, Alan F List2, David A Williams3, Peng Ji1.   

Abstract

The myelodysplastic syndromes (MDSs) include a spectrum of stem cell malignancies characterized by an increased risk of developing acute myeloid leukemia. Heterozygous loss of chromosome 5q (del[5q]) is the most common cytogenetic abnormality in MDS. DIAPH1 is localized to 5q31 and encodes one of the formin proteins, mDia1, which is involved in linear actin polymerization. Mice with mDia1 deficiency develop hematologic features with age mimicking human myeloid neoplasm, but its role in the pathogenesis of MDS is unclear. Here we report that mDia1 heterozygous and knockout mice develop MDS phenotypes with age. In these mice, CD14 was aberrantly overexpressed on granulocytes in a cell-autonomous manner, leading to a hypersensitive innate immune response to lipopolysaccharide (LPS) stimuli through CD14/Toll-like receptor 4 signaling. Chronic stimulation with LPS accelerated the development of MDS in mDia1 heterozygous and knockout mice that can be rescued by lenalidomide. Similar findings of CD14 overexpression were observed on the bone marrow granulocytes of del(5q) MDS patients. Mechanistically, mDia1 deficiency led to a downregulation of membrane-associated genes and a specific upregulation of CD14 messenger RNA in granulocytes, but not in other lineages. These results underscore the significance of mDia1 heterozygosity in deregulated innate immune responses in del(5q) MDS.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24891322      PMCID: PMC4118486          DOI: 10.1182/blood-2014-01-552463

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

Review 1.  Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia.

Authors:  N S Young
Journal:  Semin Hematol       Date:  2000-01       Impact factor: 3.851

2.  Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2.

Authors:  J da Silva Correia; K Soldau; U Christen; P S Tobias; R J Ulevitch
Journal:  J Biol Chem       Date:  2001-03-26       Impact factor: 5.157

Review 3.  Molecular pathophysiology of myelodysplastic syndromes.

Authors:  R Coleman Lindsley; Benjamin L Ebert
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

Review 4.  Classification and prognostic evaluation of myelodysplastic syndromes.

Authors:  Mario Cazzola; Matteo G Della Porta; Erica Travaglino; Luca Malcovati
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

5.  Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

Authors:  Madhu S Kumar; Anupama Narla; Atsushi Nonami; Ann Mullally; Nadya Dimitrova; Brian Ball; J Randall McAuley; Luke Poveromo; Jeffrey L Kutok; Naomi Galili; Azra Raza; Eyal Attar; D Gary Gilliland; Tyler Jacks; Benjamin L Ebert
Journal:  Blood       Date:  2011-08-26       Impact factor: 22.113

Review 6.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors:  Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

Review 7.  Overview of myelodysplastic syndromes.

Authors:  Photis Beris; George Georgiou
Journal:  Semin Hematol       Date:  2012-10       Impact factor: 3.851

8.  Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production.

Authors:  Maria Velegraki; Evaggelia Papakonstanti; Irene Mavroudi; Maria Psyllaki; Christos Tsatsanis; Anastasis Oulas; Ioannis Iliopoulos; Pavlos Katonis; Helen A Papadaki
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

9.  Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc.

Authors:  Angela Stoddart; Jianghong Wang; Anthony A Fernald; Theodore Karrison; John Anastasi; Michelle M Le Beau
Journal:  Blood       Date:  2013-11-21       Impact factor: 22.113

Review 10.  Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.

Authors:  Aristoteles Giagounidis; Ghulam J Mufti; Pierre Fenaux; Ulrich Germing; Alan List; Kyle J MacBeth
Journal:  Ann Hematol       Date:  2013-09-10       Impact factor: 3.673

View more
  23 in total

Review 1.  The regulatory role of serum response factor pathway in neutrophil inflammatory response.

Authors:  Ashley Taylor; Stephanie Halene
Journal:  Curr Opin Hematol       Date:  2015-01       Impact factor: 3.284

2.  Loss of mDia1 causes neutropenia via attenuated CD11b endocytosis and increased neutrophil adhesion to the endothelium.

Authors:  Yang Mei; Gong Feng; Nina Rahimi; Baobing Zhao; Jingxin Zhang; Lan Cao; Jing Yang; Juehua Gao; Yihua Chen; Ronen Sumagin; William A Muller; Ling Zhang; Peng Ji
Journal:  Blood Adv       Date:  2017-08-30

3.  Mammalian diaphanous-related formin 1 (mDia1) coordinates mast cell migration and secretion through its actin-nucleating activity.

Authors:  Ofir Klein; Rebecca A Krier-Burris; Pia Lazki-Hagenbach; Yaara Gorzalczany; Yang Mei; Peng Ji; Bruce S Bochner; Ronit Sagi-Eisenberg
Journal:  J Allergy Clin Immunol       Date:  2019-07-03       Impact factor: 10.793

Review 4.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

5.  KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice.

Authors:  Yue Wei; Hong Zheng; Naran Bao; Shan Jiang; Carlos E Bueso-Ramos; Joseph Khoury; Caleb Class; Yue Lu; Kevin Lin; Hui Yang; Irene Ganan-Gomez; Daniel T Starczynowski; Kim-Anh Do; Simona Colla; Guillermo Garcia-Manero
Journal:  Blood Adv       Date:  2018-10-09

6.  An inflammatory bowel disease-risk variant in INAVA decreases pattern recognition receptor-induced outcomes.

Authors:  Jie Yan; Matija Hedl; Clara Abraham
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

7.  Errant innate immune signaling in del(5q) MDS.

Authors:  Daniel T Starczynowski
Journal:  Blood       Date:  2014-07-31       Impact factor: 22.113

8.  Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling.

Authors:  Dana C Bellissimo; Chia-Hui Chen; Qin Zhu; Sumedha Bagga; Chung-Tsai Lee; Bing He; Gerald B Wertheim; Martha Jordan; Kai Tan; G Scott Worthen; D Gary Gilliland; Nancy A Speck
Journal:  Blood Adv       Date:  2020-03-24

Review 9.  Chronic immune response dysregulation in MDS pathogenesis.

Authors:  Laura Barreyro; Timothy M Chlon; Daniel T Starczynowski
Journal:  Blood       Date:  2018-08-13       Impact factor: 22.113

Review 10.  Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.

Authors:  Joseph Cannova; Peter Breslin S J; Jiwang Zhang
Journal:  Front Med       Date:  2015-08-22       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.